ArticleBreast cancer (Dove Medical Press)2026
The Impact of Androgen Receptor Expression on Neoadjuvant Therapy in HER2-Positive Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Androgen receptor (AR) is widely expressed in breast cancer, but its predictive value in HER2-positive disease remains uncertain. This study evaluated the association of AR expression with neoadjuvant therapy (NAT) response and survival in HER2-positive breast cancer. Methods: We retrospectively reviewed 336 patients with primary HER2-positive breast cancer treated with NAT at the First Affiliated Hospital of Chongqing Medical University between December 2020 and July 2024. After screening, 210 patients were included. Clinicopathological characteristics, treatment response, and survival outcomes were analyzed. Factors associated with pathological complete response (pCR) and disease-free survival (DFS) were assessed using logistic regression and Cox proportional hazards models. The predictive value of AR expression, as well as AR/ER and AR/PR ratios, was also explored. Results: The overall pCR rate was 51.9% (109/210). In the overall cohort, higher AR expression was associated with pCR, but not with DFS or overall survival (OS). Multivariate analysis identified T stage, HER2 status, and AR expression as independent predictors of pCR. In exploratory subgroup analyses, the association between higher AR expression and improved treatment response was mainly observed in hormone receptor-negative/HER2-positive patients, in whom higher AR expression was associated with both a higher pCR rate and better DFS. No significant differences in treatment response or survival according to AR expression were observed in the HR+/HER2+ subgroup. Higher AR/ER and AR/PR ratios were associated with better treatment response, whereas the direct associations between AR expression and ER/PR levels appeared limited. Conclusion: Higher AR expression was associated with improved neoadjuvant treatment response in HER2-positive breast cancer, particularly in the hormone receptor-negative subgroup. However, given the retrospective single-center design and inconsistent findings in the overall population, the clinical value of AR assessment remains preliminary and requires validation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.